About Isconova
Isconova is a company based in Uppsala (Sweden) founded in 1999 was acquired by Novavax in June 2013.. Isconova has raised $5.02 million across 1 funding round from investors including Novavax and InnovationsKapital. Isconova has completed 1 acquisition, including Nordic Vaccine. Isconova operates in a competitive market with competitors including Serum Institute of India, Vaxcyte, Freeline, Vir Biotechnology and Biological E, among others.
- Headquarter Uppsala, Sweden
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Isconova
Isconova has successfully raised a total of $5.02M through 1 strategic funding round. The most recent funding activity was a Series A round of $5.02 million completed in June 2008. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Series A — $5.0M
-
First Round
First Round
(27 Jun 2008)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun, 2008 | Amount | Series A - Isconova | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Isconova
Isconova has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Novavax and InnovationsKapital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Founded Year | Domain | Location | |
|
Novel vaccines are developed using nanoparticle and matrix adjuvant technology.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Isconova
Isconova has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Nordic Vaccine. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Adjuvants and vaccine delivery systems were developed for needle-free administration.
|
2001 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Isconova
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Isconova Comparisons
Competitors of Isconova
Isconova operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Serum Institute of India, Vaxcyte, Freeline, Vir Biotechnology and Biological E, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Vaccines and immuno-biological drugs for infectious diseases are manufactured.
|
|
| domain | founded_year | HQ Location |
Vaccines for infectious diseases are developed using cell-free protein synthesis.
|
|
| domain | founded_year | HQ Location |
Gene therapy platform is developed for chronic disease treatments.
|
|
| domain | founded_year | HQ Location |
Developer of therapeutics for the treatment of infectious diseases
|
|
| domain | founded_year | HQ Location |
Vaccines and therapeutics for multiple diseases are developed and marketed.
|
|
| domain | founded_year | HQ Location |
AAV-based gene therapies for rare diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about Isconova
When was Isconova founded?
Isconova was founded in 1999 and raised its 1st funding round 9 years after it was founded.
Where is Isconova located?
Isconova is headquartered in Uppsala, Sweden. It is registered at Uppsala, Uppsala County, Sweden.
Is Isconova a funded company?
Isconova is a funded company, having raised a total of $5.02M across 1 funding round to date. The company's 1st funding round was a Series A of $5.02M, raised on Jun 27, 2008.
What does Isconova do?
Isconova was founded as a spin-off from SLU to further develop its ISCOM technology. The technology was invented by Professor Bror Morein. The company seeks to make it commercially available as a platform for vaccine development and improved off-the-shelf research adjuvants Isconova was a leading international vaccine adjuvant company. Isconova was developing vaccines together with partners in the human and veterinary markets. The first vaccine using Isconovas nano-particle Matrix technology, Equilis, Prequenza, was launched on the veterinary market in 2005. In the human market, a number of vaccines are under development with Isconovas third generation nano-particle, Matrix MTM. Isconovas partners included Crucell, Pfizer, Merck Co., The Jenner Institute, Genocea, and Evolva. In July 2013, the company was acquired by Novavax.
Who are the top competitors of Isconova?
Isconova's top competitors include Vaxcyte, Serum Institute of India and Biological E.
How many acquisitions has Isconova made?
Isconova has made 1 acquisition, including Nordic Vaccine.
Who are Isconova's investors?
Isconova has 2 investors. Key investors include Novavax, and InnovationsKapital.